Locust Walk

In the latest episode of Biotalk, Geoff Meyerson dives into our Q2 2024 Market Conditions Report. Biotech capital markets saw the XBI remain flat in Q2, with fewer IPOs but more capital for later-stage companies. Venture financing rebounded with $5.5 billion across 44 deals, underscoring the divide between companies able to raise capital and those struggling. Strategic transaction activity centered on Phase 2 companies and notable ex-US acquisitions. Locust Walk anticipates positive momentum, careful cash management, accessible non-dilutive capital, and a gradual recovery through 2024, leading to a stronger 2025. Listen to Biotalk here: https://lnkd.in/eh55-vmk  Download Locust Walk’s Q2 2024 Market Conditions Report: https://lnkd.in/eZuFcVpG

Congratulations to Locust Walk #client CytoReason for successfully raising an oversubscribed equity financing round of $80M. Locust Walk acted as a transaction advisor for CytoReason. The new funding will expand CytoReason’s disease models and proprietary data, enabling R&D leaders at partner companies to make strategic decisions with greater speed and precision. Read more here: https://lnkd.in/e4_vimxS Alongside our partnership on this year’s Align Summit, which focused on AI/ML, this transaction underscores Locust Walk’s commitment to supporting the AI sector on a global scale. To learn more about how we can help you achieve your corporate development objectives, visit www.locustwalk.com or reach out to a Locust Walk team member.

Our Q2 2024 Market Conditions Report highlights how there has been a substantial improvement in both the private and public biotech capital markets in H1 2024, with total deal value surpassing the total value for the entire year of 2023. However, the public markets remain challenging for earlier stage companies, and the IPO window remains largely closed, favoring later-stage companies with robust data and insider support. Download Locust Walk’s Q2 2024 Market Conditions Report to learn more about the biopharma landscapes: https://lnkd.in/eZuFcVpG

Locust Walk is #hiring an Experienced Analyst for our #Boston office! If you're passionate about biopharma corporate development and thrive in a role that involves working with multiple clients simultaneously on both strategy and execution of transaction assignments, then this opportunity is perfect for you! Come #EnjoytheRide with us! Candidates must have 2-3 years of experience in a similar life science focused role; apply directly here: https://lnkd.in/eFPRsnCK #EnjoytheRide #nowhiring #careersearch #career #lifesciencejobs #biotech #biopharma #lifescience #bostonjobs 

Each quarter, Locust Walk's deal team compiles key statistics and trends on strategic transactions and financings. Our Q2 2024 Report applies the latest data to analyze current activities in the life sciences deal landscape. While the improvements in the biopharma private and public markets signal a continued positive recovery for H2 2024, the downturn in strategic deal making and reliance on future rate cuts suggest that the biotech recovery will continue to be a gradual process. Click here to download the report: https://lnkd.in/eZuFcVpG   Next week, Locust Walk will release additional commentary on the present and future state of biopharma on our podcast, Biotalk.   #biopharma #markettrends #lifesciences #global #deals #financing #strategictransactions

Locust Walk is pleased to welcome to the team Mark Diamond, a senior pharmaceutical executive with a demonstrated record of achievement and leadership throughout his over 30-year career in pharmaceuticals and biotech. Mark joins us as a Senior Advisor and will be sourcing new clients for Locust Walk in Australia and the EU. We are excited to have him on board and look forward to the contributions he will bring to our team.

Locust Walk acted as the exclusive transaction advisor for Ascentage on their option deal with Takeda for $100M upfront, a minority equity investment, and a total of $1.3B in deal value. Congratulations to Dajun Yang, Jeff Kmetz, Thomas Knapp, Jason Fan and the rest of the Ascentage team. To learn more about how we can help you achieve your corporate development objectives, visit https://lnkd.in/exqxEqdt or reach out to a Locust Walk team member. #Biotech #Transactions #LicensingDeal #StrategicPartnerships #CrossBorder

Biotalk is Locust Walk's podcast for biotech leaders. Missed any episodes? Tune in as we delve into trends, opportunities, and industry predictions based on key statistics. Our esteemed guests include Andrew Allen, Onaiza Jilani Cadoret-Manier, Jason Kelly, Howard Federoff, Helen Ho, Errik Anderson, Shehnaaz Suliman, M.D. (MB ChB), M.B.A., M.Phil., Soufiane Aboulhouda, Kendalle Burlin O'Connell, Esq., and Stephen Sands. Listen on Spotify here: https://lnkd.in/eQpkvSZy Listen on Apple Podcasts here: https://lnkd.in/e9DQFdAd We look forward to engaging in many more enlightening discussions with leaders from across the industry.

At #BIO2024, there has been fascinating discussion around how AI is transforming R&D and business practices and its value. Locust Walk’s recent "Overview of AI in Biotech" report, underscores AI's profound influence on drug discovery and the pharmaceutical sector over the past five years, with AI-derived assets accounting for almost half of the preclinical pipeline. Moreover, AI-enabled drug firms embrace either near-term revenue-focused strategies or long-term value-driven approaches. Download the report here : https://lnkd.in/egaqv9Z6 Additionally, Locust Walk’s Daniel Brog led an informative panel discussion on “AI Partnerships: Integrating for Strategic Value” at this spring’s Align Summit. Read about the key themes emerging from this panel here: https://lnkd.in/eZhJDeGS  

The Locust Walk team kicked off #BIO2024 with an energizing BioBreak reception. We appreciate everyone who joined us! Our team had engaging conversations and formed valuable new connections.